02:15 AM EDT, 10/25/2026 (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) reported positive interim results from its late-stage trial evaluating Imfinzi in combination with Amgen's (AMG.F) Imdelltra for patients with extensive-stage small cell lung cancer. Interim data from the DeLLphi-305 phase III study showed that the treatment decreased death risk by 58%, with disease progression or death also lowering by 66%, according to an Oct. 24 release. The combo therapy was compared with patients who were treated with Imfinzi only. Additionally, the company noted that the objective response rate was six times higher, and the median duration of response was longer at 12.7 months.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.